Jane Street
BCRX icon

Jane Street’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jane Street’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$590K Buy
59,000
+3,405
+6% +$30.8K ﹤0.01% 7643
2026
Q1 		$529K Sell
55,595
-302,405
-84% -$2.35M ﹤0.01% 7919
2025
Q4 		$2.79M Buy
358,000
+43,500
+14% +$314K ﹤0.01% 4167
2025
Q3 		$2.39M Buy
314,500
+38,100
+14% +$317K ﹤0.01% 4616
2025
Q2 		$2.48M Sell
276,400
-3,900
-1% -$36.3K ﹤0.01% 4084
2025
Q1 		$2.1M Sell
280,300
-126,000
-31% -$1.02M ﹤0.01% 4271
2024
Q4 		$3.06M Sell
406,300
-55,900
-12% -$424K ﹤0.01% 3411
2024
Q3 		$3.51M Sell
462,200
-449,800
-49% -$3.42M ﹤0.01% 3449
2024
Q2 		$5.64M Sell
912,000
-4,200
-0.5% -$23.2K ﹤0.01% 2799
2024
Q1 		$4.65M Buy
916,200
+26,000
+3% +$146K ﹤0.01% 2717
2023
Q4 		$5.33M Buy
890,200
+577,200
+184% +$3.34M ﹤0.01% 2762
2023
Q3 		$2.22M Buy
313,000
+122,700
+64% +$882K ﹤0.01% 3878
2023
Q2 		$1.34M Sell
190,300
-190,100
-50% -$1.53M ﹤0.01% 4758
2023
Q1 		$3.17M Sell
380,400
-31,900
-8% -$307K ﹤0.01% 3058
2022
Q4 		$4.73M Buy
412,300
+122,600
+42% +$1.53M ﹤0.01% 2564
2022
Q3 		$3.65M Sell
289,700
-44,400
-13% -$571K ﹤0.01% 3135
2022
Q2 		$3.54M Buy
334,100
+111,200
+50% +$1.15M ﹤0.01% 3185
2022
Q1 		$3.62M Sell
222,900
-47,800
-18% -$767K ﹤0.01% 3597
2021
Q4 		$3.75M Sell
270,700
-130,900
-33% -$1.73M ﹤0.01% 3307
2021
Q3 		$5.77M Sell
401,600
-44,100
-10% -$695K ﹤0.01% 2512
2021
Q2 		$7.05M Buy
445,700
+125,100
+39% +$1.7M ﹤0.01% 2153
2021
Q1 		$3.26M Buy
320,600
+230,200
+255% +$2.37M ﹤0.01% 3091
2020
Q4 		$673K Buy
90,400
+25,200
+39% +$130K ﹤0.01% 5293
2020
Q3 		$224K Buy
+65,200
New +$279K ﹤0.01% 6287

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jane Street's BCRX Position: Q2 2026 in Review

Jane Street increased its BioCryst Pharmaceuticals (BCRX) stake by 344% in Q2 2026, buying an estimated $19.4M and bringing the position to 2,762,683 shares worth $27.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1859.

Jane Street first reported a position in BCRX in Q2 2013 and has held it in 37 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Jane Street held 2,762,683 shares of BioCryst Pharmaceuticals worth $27.6M as of Q2 2026.
  • Jane Street bought 2,140,076 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $19.4M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #1859 holding.
  • Jane Street first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.